TheFinRate
All Tags

#HealthcareStocks

1 article

Sun Pharma Added to Citi's Pan-Asia Focus List With 35% Upside Potential

Sun Pharma Added to Citi's Pan-Asia Focus List With 35% Upside Potential

Sun Pharma has been added to Citi’s Pan-Asia Focus List with a 35% upside potential. The brokerage expects innovation revenues to triple by FY30, driven by key drug approvals and expanded Medicare coverage. Despite mixed analyst views, Sun Pharma remains one of Asia’s most closely watched pharmaceutical stocks.